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Background: Castration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The
primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblastic
and osteolytic lesions. Recently, cabozantinib, a multi-kinase inhibitor (VEGFR2 and c-MET inhibitor), was shown to
have efficacy on bone lesions in patients. In this study we tested multi-kinase inhibitors: axitinib (VEGFR inhibitor)
and crizotinib (c-MET inhibitor) in a combination trial in mice models.
Methods: VCaP-Luc cells were grown as subcutaneous implants in intact and castrated NOD-SCID-gamma (NSG) mice
to confirm the androgen dependency. For bone metastasis model two cohorts of NSG mice (castrated and intact)
received orthotopic injection of VCaP-Luc cells into the bone marrow cavity of left tibia. Mice were monitored weekly
for tumor growth using bioluminescence imaging. Animals were randomized into 4 groups based on the tumor
bioluminescence signal: vehicle, crizotinib alone, axitinib alone, crizotinib and axitinib in combination. Animals were
imaged weekly by in vivo 2-D X-ray imaging to monitor bone remodeling. At the end of the study animals were
euthanized and both tibias were extracted for ex vivo high-resolution 3-D micro-computed tomography (μCT) imaging.
Results: Subcutaneous model showed that androgen stimulation may be helpful but not essential for the growth of
VCaP-Luc cells. VCaP-Luc cells grown intra-tibially in intact animals caused extensive remodeling of bone with mixed
osteoblastic (bone formation) and osteolytic (bone matrix dissolution) lesions. The osteoblastic lesions were predominant
and at times extended beyond the tibial shaft into the surrounding tissue. In contrast, only osteolytic lesions were
prominent throughout the study in castrated animals. Treatment with crizotinib alone reduced the osteolytic lesions in
castrated animals. Axitinib alone reduced the osteoblastic lesions in the intact animals. Combination therapy with axitinib
and crizotinib remarkably inhibited the tibial remodeling by VCaP-Luc cells which resulted in a significant reduction of
both osteoblastic and osteolytic lesions.
Conclusion: Our data show that combined inhibition of c-MET and VEGFR can be beneficial for treatment of metastatic
bone disease in CRPC and that the drugs act on two different stages of the disease.
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Prostate cancer (PC) is the second leading cause of
new cancer cases in men worldwide. According to the
Centers for Disease Control and Prevention (CDC),
PC is the most commonly diagnosed malignancy and the
second leading cause of cancer related deaths among
men in the USA [1]. Due to advances in screening
and prevention, most PC cases are detected at early
stages. Although localized PC can be treated with one
or a combination of therapeutic modalities [2], many
patients nonetheless go on to develop metastatic disease,
especially in the local lymph nodes and bones. Currently
androgen deprivation therapy (ADT) represents the
primary treatment for metastatic PC. Unfortunately,
after an initial benefit from androgen deprivation, PC
often progresses after 12–48 months resulting in a
more aggressive castration resistant prostate cancer
(CRPC) form of the disease [3].
The primary cause of mortality and morbidity in
CRPC patients is bone metastases, with local disruption
of normal bone remodeling secondary to an increase in
osteoblastic and osteolytic lesions. Metastatic bone lesions
eventually lead to bone weakening which can result in
skeletal fractures, spinal cord compression, intractable
bone pain, cachexia and death [4]. The standard of care
(SOC) therapy for patients at this stage of disease is
chemotherapy (Docetaxel) with or without prednisone [5].
Chemotherapy improves survival but has no effect on the
metastatic bone lesions. In addition, osteoblastic or mixed
(osteoblastic and osteolytic) metastatic bone lesions
associated with PC are poorly responsive to osteoclast
inhibitors [6]. Therefore, a treatment that can reduce
primary prostatic tumors and metastatic bone lesions
could provide a significant improvement in the quality of
life for patients with advanced disease [7].
Recently, a multi-targeted tyrosine kinase inhibitor
cabozantinib (XL-184) [8] was shown to reduce bone
lesions, improve pain management and offer some
survival benefit in CRPC patients. It was proposed that
the observed effect was due to dual inhibition of vascular
endothelial growth factor receptor 2 (VEGFR2) and
hepatocyte growth factor (HGF) receptor c-MET [9],
however the exact mechanism of action of cabozantinib
remains to be further understood. It is known that
angiogenesis plays an important role in PC progression and
metastasis [10,11]. VEGFR expression has been associated
with worse prognosis in several cancers, including prostate
cancer [12]. In addition to its effect on endothelial cells,
VEGFR activation also stimulates osteoblast migration
[13] and differentiation [14], suggesting that VEGF/VEGFR
pathway may contribute to bone lesions in metastatic PC
[15,16]. Under normal conditions, c-MET is an important
mediator of organogenesis, tissue regeneration and
angiogenesis. In the normal prostate epithelium, c-MET isspecifically expressed in basal and atrophic luminal cells
[17]. In PC, an increase in c-MET expression was
observed [18,19] and appeared to be associated with
progression of bone metastasis [20,21]. Moreover, an
inverse relationship between androgen level and c-MET
expression has been observed in prostate cancer cell
lines [18], suggesting that androgen deprivation, the
current approach to metastatic PC may negatively con-
tribute to disease response by increasing the expression of
c-MET [22].
To gain additional insight into the potential clinical
relevance of targeting both VEGFR2 and c-MET in men
with PC bone metastases, we tested the effect of axitinib
(VEGFR inhibitor) [23] and crizotinib (c-MET inhibitor)
[24], either as single agents or in combination, in an
orthotopic bone metastasis model of PC in both intact
and castrated NSG mice [25]. In intact mice, VCaP-Luc
cell infiltration into bone caused extensive remodeling of
bone with mixed lesions (osteoblastic and osteolytic),
whereas in castrated animals osteolytic lesions were more
prominent indicating a potential role of androgen in the
bone phenotype of the disease. Treatment with crizotinib
alone reduced the osteolytic lesions seen in castrated
animals. Axitinib alone reduced the osteoblastic lesions in
the intact animals. Combination therapy with axitinib and
crizotinib had a remarkable effect in inhibiting the tibial
remodeling with a reduction of both osteoblastic and
osteolytic lesions. These results show that combined
inhibition of c-MET and VEGFR2 can be beneficial for the
treatment of metastatic bone disease in a CRPC model




The following compounds were generated at Pfizer: axitinib
(AG013736; trade name Inlyta®) [23] and crizotinib
(PF-02341066; trade name Xalkori®) [24].
Cell line and animals
Human prostate cancer line VCaP was obtained from
American Type Culture Collection (catalog #CRL-2876;
ATCC, Manasas, VA) and maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS). VCaP-Luc cell line was made
by transfection with vector pLPCX: Luc-SH and selected
with puromycin. Male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mice which were 6–8 week old was purchased from
Jackson Laboratory (Bar Harbor, ME) and housed in barrier
rooms under pathogen-free conditions. All animal
experiments were carried out in compliance with Pfizer’s
Institutional Animal Care and Use Committee (IACUC)
guidelines and in accordance with the “Guide for the
Care and Use of Laboratory Animals” by the Institute of
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(ILARCLS, National Research Council, Washington D.C.).
All animal handling and surgical procedures were
performed using protocols approved by Pfizer’s IACUC.
For castration, animals were anesthetized using Ketamine/
Xylazine via intraperitoneal route and castration was
performed by a scrotal incision procedure. Animals were
allowed to recover from surgery for 2 weeks before being
enrolled in experiments.
Subcutaneous tumor model
VCaP-Luc cells (1 × 106 cells/animal) were implanted
subcutaneously into the flank of ~10 week old male
NSG mice. Ten of the NSG mice were castrated before cell
implantation (labeled as “castrated”), ten were castrated
5 weeks after cell implantation (labeled as “intact-castrated”)
and ten received sham surgery (labelled as “intact”). Tumor
volume was calculated based on weekly caliper measure-
ment using the formula: volume = (width)2 × length /2.
Intra-tibial tumor model
Orthotopic bone tumor model was performed based on
Park et al. [26] and Corey et al. [27] with minor modifica-
tions. Briefly, ~10 week old male NSG mice with or without
castration were anesthetized by administering a mixture of
ketamine and xylazine via intraperitoneal route. A small
hole was drilled proximal to the tibial tuberosity with a
19-gauge needle. After penetration of the cortical bone, an
intraosseous injection of 30ul sterile PBS containing
1 million VCaP-Luc cells in suspension was administered.
Tumor growth was monitored by plasma PSA, biolumines-
cence imaging (BLI by IVIS-200) and X-ray (by Faxitron).
Drug treatment was initiated 4 weeks after tumor implant-
ation. Tumor-bearing mice were randomized based on BLI
measurements and enrolled into 4 treatment groups
(n = 10 mice/group): vehicle, crizotinib (50 mg/kg,
oral QD) only, axitinib (30 mg/kg, oral BID) only and
crizotinib (50 mg/kg, oral QD) + axitinib (30 mg/kg,
oral BID). At the end of the study, tibias of both the
control and tumor bearing limb from all animals was
collected for μCT analysis. The bones were immersed in
10% neutral buffered formalin (NBF) for 3 days for
fixation. The tissues were then removed from NBF
and wrapped in saline soaked gauze for storage at −80°C
until μCTanalysis.
Immunohistochemistry
Tibias from intact or castrated mice bearing VCaP-Luc
tumor were collected, fixed in 10% NBF, decalcified,
paraffin embedded and sectioned at a thickness of 5 μm.
Slides were baked, loaded onto Leica Bond III automated
IHC/ISH strainer (Leica Microsystems, Inc., Bannockburn,
IL), and deparaffinized with BOND dewaxing solution
(Leica Microsystems). Antigen retrieval was achieved byexposing the tissue slides to Epitope Retrieval Solution 2
(Leica Microsystem) for 30 minutes, and then quenching
endogenous peroxidase by incubating with 3% hydrogen
peroxide. After multiple washing steps, slides were
incubated with primary antibody (rabbit anti-human
c-MET monoclonal antibody, clone SP44) (Spring
Bio/Ventana/Roche, Pleasanton, CA) or rabbit IgG as
negative control (Cell Signaling Technology, Inc.,
Danvers) for 60 minutes and detected by using Bond
Polymer Refine Detection Kits (Leica Microsystems),
followed by counterstaining with hematoxylin. Slides
were dehydrated, cleared, and mounted with cover slips.
All the images were visualized using Nikon ECLIPSE
E-400 Microscope (Nikon Microscope) and captured
through a SPOT Insight Color Mosaic 11.2.1 camera using
SPOT Software, V4.7.
Western blotting
Subcutaneous tumor samples were collected and frozen
immediately in liquid nitrogen when they reached
800 mm3. To prepare lysate, snap-frozen tumor frag-
ments were lysed in FastPrep Lysing Matrix A tubes
according to manufacturer’s recommendations (MP
Biomedicals, Santa Ana, CA). Following protein meas-
urement by BCA (Thermo Scientific, Waltham, MA),
20 μg of each lysate was electrophoresed, transferred to
nitrocellulose membrane using the iBlot Dry Blotting
System (Invitrogen, San Diego CA). The anti-androgen
receptor antibody PG-21 (EMD Millipore, Temecula,
CA) was used as primary antibody for detecting AR.
Anti-β-actin antibody AC15 (Sigma-Aldrich, St. Louis,
MO) was used as control.
ELISA measurement of plasma PSA
Plasma was obtained every 2 weeks for measurement of
PSA levels using Quantikine human PSA immunoassay kit
(R&D Systems, Minneapolis, MA) as per manufacturer’s
instructions.
Bone imaging and analysis
Mouse tibias were initially imaged by X-ray (Faxitron
MX20; Faxitron Bioptics, LLC; Tuscon, Arizona) once a
week throughout the study using the following parameters:
20kv and 5 s exposure time. At the end of the study tibias
from both legs were collected and imaged ex vivo by μCT
(vivaCT 75; Scanco Medical AG; Basserdorf, Switzerland)
in high resolution using the following parameters: 70kVP,
114 μA, 300 ms integration time, 20.5-μm voxel size. The
scanning protocol was programmed to acquire images via
a rotating gantry, resulting in a total of 2,000 projections
per scan. The projections were reconstructed with a matrix
of 2048 × 2048 using the software provided by Scanco
Medical. A 615-μm-thick cross-section of the cancellous
bone at the proximal tibial epiphysis, including the primary
Figure 1 Characterization of subcutaneous xenograft model of
VCaP-Luc. (A) Tumor growth curves of VCaP-Luc cells subcutaneously
implanted in intact (sham surgery), castrated (castrated before tumor
implantation) and intact-castrated mice (castrated 5 weeks after tumor
implantation, as indicated by the arrow). Error bar represents SEM of
n = 10 mice/group. (B) Western blot of androgen receptor expression
in VCaP-Luc subcutaneous tumors grown in intact (I), castrated (C) and
intact-castrated (I-C) mice. Tumors were harvested at approximately
800 mm3. Representative image from 3 tumor samples.
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the growth plate. An optimized input threshold of 175 was
selected over the software default threshold of 220 based
on a visual assessment of the quality of segmentation. Bone
structural parameters such as connectivity density (Conn.
D), structure model index (SMI), bone mineral density
(BMD), bone volume fraction (BV/TV), and trabecular
number, thickness, and separation (Tb.N, Tb.Th, and Tb.
Sp, respectively) were ascertained using Scanco’s μCT
Evaluation Program V6.5-1. Images were later converted to
2D binary digital imaging communication (DICOM) files
and imported into 64-bit OsiriX (Opensource software) for
image reconstruction.
Statistical analysis
Data are expressed as mean ± SEM unless indicated other-
wise. Statistical significance was determined by analysis of
variance (ANOVA) using Dunnett’s multiple-comparison
post test with GraphPad Prism® software unless otherwise
noted.
Results
Characterization of VCaP-Luc as a subcutaneous model
To facilitate longitudinal measurement of the orthotopically
grown tumors, we generated bioluminescence capable
cell line VCaP (VCaP-Luc) by transfection with a
luciferase-encoding vector. VCaP-Luc was first grown
as a subcutaneous model in NSG mice (intact and
castrated) to evaluate its androgen dependency and
growth characteristics. Palpable tumors were seen
about 4 weeks after implantation (Figure 1A). Tumors
grew at a slightly faster rate in the intact animals
suggesting that the cell line is responsive to androgen
stimulation. Half of these intact animals were castrated at
5 weeks post implantation to observe the effect of
androgen deprivation. Following castration the tumors
showed a delayed growth rate but were still able to grow
to size of 1500 mm3 by 10 weeks post-implantation
(Figure 1A). A similar effect was seen with animals that
had been castrated prior to tumor implantation (Figure 1A).
At the end of the study tumors were evaluated for
androgen receptor (AR) expression using western blot
analysis. Data (Figure 1B) show that the tumors in all
three groups have detectable levels of AR with a
slight increase in expression in the castrated animals.
These results indicate that the VCaP-Luc cell lines
maintain the parental characteristics post-transfection
with luciferase gene, and that androgen stimulation is
helpful but not essential for growth of the cell line.
Intra-tibial model characterization
Following intra-tibial injection of VCaP-Luc cells to NSG
mice (intact and castrated) as described in Materials and
Methods section, tumor growth was monitored usingbioluminescent imaging (BLI) and Faxitron imaging
(X-ray). The results showed that tumor growth rates
in this model were different between the castrated
and intact animals. Tumor growth in intact mice was
detectable 4 weeks post-implantation using BLI with an
average luminescence intensity of 2 × 107 photons/second.
Tumors continued to progress and reached 3 × 107
photons/second by 9 weeks post-implantation (Figure 2A).
Faxitron imaging of these tibias showed that during the
observation period, there was an initial loss of bone
density between 5–7 weeks (Figure 2B). However, by
about 8 weeks bone proliferation was seen by increased
bone density and formation of bone spicules radiating
from the bone shaft. By about 9 weeks some of these
proliferative bone lesions were seen to extend out
into the surrounding soft tissue space. At this stage,
the animals reached the end point for lameness and
had to be terminated. In castrated mice, the tumors
Figure 2 Characterization of intra-tibial bone metastasis model of VCaP-Luc. (A) Measurement of intra-tibial tumor growth in intact
(sham surgery) and castrated (castrated before intra-tibial injection of tumor cells) NSG mice by bioluminescence imaging once a week. Error bars
represent SEM of n = 10 mice/group. (B) Faxitron and μCT imaging of intra-tibial PC model in intact mice. Faxitron imaging (in vivo) was performed
at indicated time intervals during the study. The inset of Faxitron imaging shows control leg (no intra-tibial tumors) and tumor leg (received VCaP cell
intra-tibially) at week 9. Ex vivo μCT imaging was performed and reconstructed at the termination of the study (week 9). Control leg and tumor legs
after 3-D reconstruction is shown. (C) Faxitron and μCT imaging of intra-tibial PC model in Castrated mice. Faxitron imaging (in vivo) was performed
at indicated time intervals during the study. The inset of Faxitron imaging shows control leg (no intra-tibial tumors) and tumor leg (received VCaP-Luc
cells intra-tibially) at week 9. Ex vivo μCT imaging was performed and reconstructed at the termination of the study (week 9).
Control leg and tumor legs after 3-D reconstruction is shown.
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photons/second) between 5–7 weeks post-implantation in
all animals. The tumors continued to progress and reached
3 × 107 photons/second by 10–11 weeks. Faxitron imaging
of the implanted tumors in these animals showed a pre-
dominantly osteolytic phenotype with loss of bone density
throughout the 11 weeks of monitoring. Animals had to be
euthanatized at this point due to lameness endpoint
(Figure 2C). Histopathologic section of the tumor-laden
tibia revealed regionally extensive invasion and effacement
of normal bone architecture extending from within the
marrow cavity into the adjacent epiphysis, metaphysis,
diaphysis, and growth plate. Areas of osteolysis admixed
with occasional osteoclasts and areas of attempted repair
with plump osteoblasts are interspersed throughoutregions of cancellous and cortical bone (Additional file 1:
Figure S1). C-Met expression in the tumor cells was seen
in both intact and castrated tibias. Interestingly, the c-Met
staining was both diffusely cytoplasmic and membranous
in the intact mice tibias, while in castrated mice the
staining was predominantly membranous (Additional file 2:
Figure S2). This differential expression and localization
could be indicative of the different cell phenotypes seen in
the bone of these mice.
Effect of targeting VEGFR and c-MET in VCaP-Luc
intra-tibial tumor model
We next tested the efficacy of kinase inhibitors targeting
VEGFR (axitinib) and c-MET (crizotinib) in this model.
In addition to BLI and X-ray imaging modalities, we also
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bone phenotype. Tumor evaluation using BLI imaging
showed that treatment of intact tumor-bearing animals
with axitinib alone or axitinib and crizotinib in combination
led to statistically significant reduction in tumor pro-
gression compared with vehicle treated animals by day 34
(Figure 3A). This reduction in tumor size correlated to aFigure 3 Efficacy of axitinib and crizotinib in intact and
castrated tumor bearing mice by bioluminescence imaging.
(A) Bioluminescence measurement of treatment groups on day 34
in intra-tibial VCaP tumor model in intact mice. (B) PSA levels during
the course of treatment in intact mice bearing intra-tibial VCaP-Luc
tumor. (C) Bioluminescence measurement of treatment groups on
day 34 in intra-tibial VCaP tumor model in castrated mice. PSA
levels in all groups of castrated mice were below level of detection
(data not shown). *p < 0.01, compared to vehicle group. Error bar
represents SEM of n = 10mice/group.lower plasma PSA levels between Day 10 and the end of
the study in these groups compared to vehicle treated
animals and animals receiving crizotinib alone (Figure 3B).
Animals treated with crizotinib alone had no statisti-
cally significant reduction in tumor size (Figure 3A) and
showed no reduction in plasma PSA levels (Figure 3B)
indicating that targeting c-MET alone is not sufficient.
In the castrated group, axitinib alone or axitinib in
combination with crizotinib resulted in a statistically
significant reduction in tumor burden by day 34 (Figure 3C).
Though there was a visible reduction in tumor burden in
crizotinib alone group, it was not statistically significant
(Figure 3C). PSA levels in the castrated mice were below
the threshold detection level of 10-20 ng/ml in all groups
(data not shown) and thus suggest PSA may not predict the
tumor burden.
Image analysis (assessed by Faxitron and μCT imaging)
of the tumor bearing tibias showed that intact animals in
vehicle-treated group developed mixed osteolytic and
osteoblastic tumor-associated lesions (Figure 4A). Despite
the presence of extensive proliferative bone lesions on the
X-ray images, bone density was poor compared to that of
the normal bone (control right leg) and the bone volume
(ratio of bone volume to trabecular volume (BV/TV)) was
approximately 35% less than that of the normal bone
(Figure 4B). In the axitinib treated group, Faxitron
imaging from 5–9 weeks showed that there was very
little loss of bone tissue contrast and no significant
bony proliferation. Ex vivo μCT analysis of the tibias
on the other hand showed a mild increase in the
bony proliferation exhibited as scalloping of the bone
diaphysis (Figure 4A). In the crizotinib alone treated
group, proliferative osteoblastic lesions were very evi-
dent and similar to that of the vehicle treated groups.
Additionally the areas of osteolysis in the bone were
less than that observed in the vehicle treated animals
(Figure 4A). In the animals treated with the combination
of axitinib and crizotinib the tumor bearing bones had
very little evidence of osteoblastic or osteolytic bone
remodeling (Figure 4A) indicating that this combination
therapy was very effective in the prevention of bone
remodeling induced by the tumor in intact mice.
Additionally, the phenotype and BV/TV ratios were
similar in axitinib alone or combo therapy groups. In
the vehicle-treated castrated cohort, Faxitron images
showed a gradual reduction in bone density from
week 5 to 11 (Figure 5A). Ex vivo μCT of the bones
confirmed the osteolytic lesions in vehicle-treated mice
(Figure 5A). The bone density was poor compared to that
of the normal bone (control right leg) and the BV/TV
ratio was approximately 25% less than that of the
normal bone (Figure 5B). Treatment with axitinib alone
did not have any effect on the loss of radiodensity on
Faxitron, osteolytic lesions or BV/TV ratio by the μCT
Figure 4 Efficacy of axitinib and crizotinib in intact tumor
bearing mice by in vivo Faxitron X-ray and ex vivo μCT
imaging. (A) Faxitron and μCT imaging in intact mice model.
Faxitron images were taken at indicated time intervals during the
study, whereas μCT images were taken and reconstructed at the
termination of the study (week 9). μCT images show the 3-D of the
tibial length and a tibial cross-section. (B) Quantitation of Intra-tibial
tumor model in Intact mice: BV/TV ratios were determined by
Scanco software after μCT imaging. ** (black) is vehicle vs control
leg; * (red) treatment vs vehicle. *p < 0.01; **p < 0.001. Error bars
represent SEM of n = 10 mice/group.
Figure 5 Efficacy of axitinib and crizotinib in castrated tumor
bearing mice by in vivo Faxitron X-ray and ex vivo μCT
imaging. (A) Faxitron and μCT imaging in castrated mice model.
Faxitron images were taken at indicated time intervals during the
study, whereas μCT images were taken and reconstructed at the
termination of the study (week 9). μCT images show the 3-D of the
tibial length and a tibial cross-section. (B) Quantitation of Intra-tibial
tumor model in Castrated mice: BV/TV ratios were determined by
Scanco software after μCT imaging. ** (black) is vehicle vs control
leg; * (red) treatment vs vehicle. *p < 0.01; **p < 0.001. Error bars
represent SEM of n = 10 mice/group.
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crizotinib and axitinib combination groups the loss of
bone density on Faxitron and μCT was very minimal,
indicating that these treatments prevented the bone
loss initiated by the tumor proliferation (Figure 5B).
Discussion
Prostate Cancer (PC) represents a major health issue in
men with an estimated 240,000 new cases and almost
30,000 deaths annually in the United States [28]. Although
surgery and radiation therapy has cured many patients
with PC, more than one third of the patients will
eventually progress and develop advanced disease, for
which ADT is the standard of care. Unfortunately, most
patients who undergo chemical or surgical castration will
eventually progress and develop CRPC [29,30]. There have
been numerous studies attempting to understand the
mechanisms and processes for the development of
CRPC, some of which include ligand-independent AR
activation, AR mutations, amplification and selection of
pre-existing androgen independent cells that are resistant
to apoptosis [31,32].
Bone is the most common site of metastases in
men with advanced PC. Historical data shows that
the overwhelming majority (more than 80%) of PC
patients eventually develop bone disease [6,7,33]. Cancer
metastases in the bone usually lead to disturbance of bone
formation and resorption, resulting in osteolytic and/or
osteoblastic lesions [34-36]. It remains largely unclear what
factors determine whether a particular bone metastasis is
osteolytic, osteoblastic or of mixed phenotype, although
some studies suggested that different types of cancer have
the propensity to secrete more osteoblastic or osteolytic
factors [37]. In this study, we observed different bone
phenotypes between castrated and intact host mice intra-
tibially implanted with VCaP-Luc cell line. Although this
cell line is classified as a castration-resistant prostate cancer
line, its growth rate was reduced in castrated mice
compared with intact mice, in both subcutaneous and
intra-tibial growth conditions. This difference may
lead to difference in growth characteristics of the cells
and in the type of paracrine factors that affect the activation
of osteoblasts and osteoclasts. Regardless of the phenotype,
bone metastases usually lead to compromised bone integ-
rity and strength, and as a result, increased incidence of
fractures, spinal cord compression and severe pain
[38,39]. These are not only quality of life issues, but
also directly worsen the survival span of the patients.
Thus, effective prevention and management of bone
metastases is critical for reducing PC related morbidity
and mortality. Until recently, there have been limited
choices for therapeutic intervention of metastasis-induced
bone loss. Although zoledronic acid has been used to
prevent bone loss, its long term benefit is not welldefined [40]. Newer agents such as Denosumab [41]
and cabozantinib [42] have shown clinical benefit in
delaying the occurrence of skeletal-related events
(SRE) in PC patients.
Crizotinib is a potent and selective inhibitor of c-MET
and several related tyrosine kinases. C-MET and its
ligand, hepatocyte growth factor (HGF), are involved
in cell proliferation, differentiation, motility and survival
[43]. Crizotinib exhibited a dose-dependent anti-tumor
effects by inhibition of tumor cell proliferation, micro
vessel density and angiogenesis [44]. Tumor effects due to
in prostate cancer, c-MET expression is elevated in bone
metastases compared with lymph node metastases or
primary tumors [19], and in tumors in castrated patients
compared with non-castrated patients [45]. In addition,
c-MET pathway is believed to play a role in proliferation,
differentiation and migration of osteoblasts and osteoclasts
[46,47]. The c-MET ligand, HGF can be secreted by
multiple cell types including osteoclasts and mesenchymal
cells, potentially forming autocrine and paracrine regulation
of bone remodeling [46]. Axitinib the other kinase inhibitor
used in this study is a potent and selective inhibitor
of angiogenesis targeting VEGFR2. Elevated levels of
circulating VEGF have been correlated with poor
prognosis in PC patients [48]. VEGF and its receptors
are shown to be expressed in osteoblasts and osteoclasts
[49], exerting multiple functions through autocrine and
paracrine activation of the VEGFR pathway. Taking into
account the function of c-MET and VEGFR in PC
metastasis, we hypothesized that blocking both pathways
simultaneously by combining two targeted agents may
offer substantial benefit to PC patients. Our data
showed that axitinib alone or axitinib and crizotinib
in combination reduced the tumor burden in both intact
(androgen positive) and castrated (androgen negative)
mice models (Figure 3A and 3C). Interestingly only the
axitinib and crizotinib combination showed improvements
of bone volume (BV/TV ratio) in both models (Figure 4B
and 5B). This suggested that combination therapy had
clear benefit on tumor burden and bone volume in
both intact (androgen positive) and castrated (androgen
negative) mice models of PC. The combination can also
be achieved by a single agent with dual or multiple
specificities as indicated by cabozantinib, a potent inhibi-
tor of receptor tyrosine kinases including MET, VEGFR2,
AXL, FLT-3, KIT, and RET [9]. In fact, a phase II adaptive,
randomized discontinuation trial of cabozantinib in
patients with metastatic CRPC [42] has generated
encouraging results showing clear improvements in
bone scans in 68% of evaluable patients. On the other
hand, co-administration of two separate compounds
(such as crizotinib and axitinib) would allow flexibility
when the dosage of each compound or pathway needs
modification.
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Our results show that co-administration of c-MET
(Crizotinib) and VEGFR2 (Axitinib) inhibitors suppressed
tumor growth and maintained bone phenotype. Combined
inhibition of c-MET and VEGFR can be beneficial for
treatment of metastatic bone disease in CRPC and that
the drugs act on two different stages of the disease.
Additional files
Additional file 1: Figure S1. H and E staining of the normal tibia and
intra-tibial VCaP model of PC. Tumor bearing tibias show infiltration of
osteoblasts and osteoclasts into the growth plate, epiphysis and diaphysis.
Additional file 2: Figure S2. Differential c-Met immunostaining in
tumor bearing intact and castrated tibias. Intact mice tibias showed both
diffused cytoplasmic and membranous staining of c-MET, whereas in
castrated mice the c-MET staining was primarily at the cell membrane.
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